ArticleProbiotics and antimicrobial proteins2026
Cold-Active Postbiotics from Fermented Food-Derived Lactobacillus fuchuensis H.Y.35 Exhibit Multifunctional In Vitro Bioactivities.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Postbiotics are stable, non-living microbial products that provide health benefits similar to probiotics and have lower safety concerns. Despite the expanding recognition and use of postbiotics, little is known about the specific properties and applications of postbiotics derived from cold-active (psychrophilic or psychrotolerant) microbial strains. To identify the molecular mechanisms that underpin therapeutic applications, we isolated cold-active probiotic candidates at 4 °C from fermented foods (feta cheese and kefir) sourced from local markets. Cell-free supernatant (CFS) of the isolates was initially screened for antioxidant activity, then followed by assessment of antimicrobial effects against Escherichia coli, Staphylococcus aureus, and Staphylococcus epidermidis. Cold-active Lactobacillus fuchuensis H.Y.35 showed strong antioxidant and antimicrobial capacities compared to other isolates. Antifreeze and cryoprotective assays confirmed that H.Y.35 postbiotics inhibited ice recrystallization and reduced drip loss in frozen cells. Untargeted metabolomics of H.Y.35 CFS identified bioactive compounds, including phenolic acids, fatty acyl derivatives, and amino acid-based metabolites. These bioactive compounds are linked to radical scavenging, antimicrobial activity, and cryoprotection. Complementary proteomic analysis further revealed the enrichment of proteins involved in stress adaptation, antimicrobial defense, and cryoprotection. These detected compound include pseudouridine synthase, cyclic-di-AMP phosphodiesterase, RNA polymerase sigma factor SigA, and the Sakacin Q immunity protein. These findings provide molecular evidence supporting the multifunctionality of cold-active postbiotics. The Lactobacillus fuchuensis H.Y.35 postbiotics/CFS also demonstrated potent wound-healing activity in vitro at 1% and 10% (v/v) concentrations, achieving up to 100% closure within 24 h (p < 0.01). This multifunctionality highlights the biotechnological and therapeutic potential of cold-active postbiotics as natural agents for health and industrial applications.
Indexed as
Identifiers
42213390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.